INTRATUMORAL EXPRESSION OF PD-1/PD-L1 IMMUNE CHECKPOINT IN PATIENTS WITH HEPATOCELLULAR CARCINOMA

被引：0

作者：

Baquerizo, Angeles ^{[1
,2
]}

Vavinskaya, Vera ^{[3
]}

Rojas, Angela ^{[4
]}

Mhoyan, Anna ^{[5
]}

Romero-Gomez, Manuel ^{[6
]}

Sher, Linda ^{[7
]}

Madani, Bahar ^{[2
]}

Fisher, Jonathan ^{[1
]}

Schaffer, Randolph ^{[1
]}

Frenette, Catherine T. ^{[8
]}

Marsh, Christopher ^{[9
]}

机构：

[1] Scripps Hlth, Surg, La Jolla, CA USA

[2] Scripps Clin, La Jolla, CA 92037 USA

[3] UCSD, Pathol, La Jolla, CA USA

[4] Virgen Del Rocio Univ Hosp, Hepatol, Seville, Spain

[5] Kaiser, Pathol, San Diego, CA USA

[6] Virgen Del Rocio Univ Hosp, Seville, Spain

[7] USC, Los Angeles, CA USA

[8] Scripps Hlth, Scripps Clin, La Jolla, CA USA

[9] Scripps Hlth, La Jolla, CA USA

来源：

HEPATOLOGY | 2019年 / 70卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

321

引用

页码：206A / 206A

页数：1

共 50 条

[41] Exploring immune checkpoint inhibitors: Focus on PD-1/PD-L1 axis and beyond
Aden, Durre
Zaheer, Samreen
Sureka, Niti
Trisal, Monal
Chaurasia, Jai Kumar
Zaheer, Sufian
PATHOLOGY RESEARCH AND PRACTICE, 2025, 269 : 155864
[42] PD-1/PD-L1 checkpoint blockade in immune-antitumortherapy:advances and perspectives
Yu LI
Ji JIANG
Bei HU
中国药理学与毒理学杂志, 2017, 31 (10) : 963 - 963
[43] Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies
Dongxu Wang
Jianzhen Lin
Xu Yang
Junyu Long
Yi Bai
Xiaobo Yang
Yilei Mao
Xinting Sang
Samuel Seery
Haitao Zhao
Journal of Hematology & Oncology, 12
[44] Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies
Wang, Dongxu
Lin, Jianzhen
Yang, Xu
Long, Junyu
Bai, Yi
Yang, Xiaobo
Mao, Yilei
Sang, Xinting
Seery, Samuel
Zhao, Haitao
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2019, 12 (1)
[45] Prospective role of PD-1/PD-L1 immune checkpoint inhibitors in GI cancer
AmeliMojarad, Mandana
AmeliMojarad, Melika
Cui, Xiaonan
PATHOLOGY RESEARCH AND PRACTICE, 2023, 244
[46] The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma
Mahoney, Kathleen M.
Freeman, Gordon J.
McDermott, David F.
CLINICAL THERAPEUTICS, 2015, 37 (04) : 764 - 782
[47] Immune checkpoint inhibitors targeting PD-1/PD-L1 in the treatment of human lymphomas
Ribatti, Domenico
Cazzato, Gerardo
Tamma, Roberto
Annese, Tiziana
Ingravallo, Giuseppe
Specchia, Giorgina
FRONTIERS IN ONCOLOGY, 2024, 14
[48] Investigation of the status of immune checkpoint molecules (PD-L1 and PD-1) in meningiomas by immunohistochemistry
Saygin, Ismail
Cakir, Emel
Kazaz, Seher Nazli
Guvercin, Ali Riza
Eyupoglu, Ilker
Ustaoglu, Muserref Muge
TURKISH JOURNAL OF MEDICAL SCIENCES, 2024, 54 (04) : 735 - 743
[49] PD-L1 expression and PD-1/PD-L1 inhibitors in breast cancer
Monneur, Audrey
Goncalves, Anthony
Bertucci, Francois
BULLETIN DU CANCER, 2018, 105 (03) : 261 - 272
[50] Anti PD-1/PD-L1 Immune checkpoint inhibitors - addition - EML and EMLc
SELECTION AND USE OF ESSENTIAL MEDICINES: REPORT OF THE WHO EXPERT COMMITTEE ON SELECTION AND USE OF ESSENTIAL MEDICINES, 2019 (INCLUDING THE 21ST WHO MODEL LIST OF ESSENTIAL MEDICINES AND THE 7TH WHO MODEL LIST OF ESSENTIAL MEDICINES FOR CHILDREN), 2019, 1021 : 314 - 331

← 1 2 3 4 5 →